Physician profile
Angus C Howard
NPI 1003858051
$2,145.16
in general payments reported to CMS, 2019-2025
22 companies · $61.70 in 2025
The $61.70 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $255 · 2021: $436 · 2022: $258 · 2023: $436 · 2024: $225 · 2025: $61.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.06 |
| Education | $101.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $295.59 | 2019-2023 | Auryxia |
| Amgen INC. | $229.44 | 2019-2023 | Tavneos |
| Opko Pharmaceuticals, LLC | $187.10 | 2019-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $168.06 | 2019-2024 | Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $163.67 | 2021 | |
| Vifor Pharma, INC. | $153.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $149.64 | 2021-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $120.65 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $106.50 | 2022-2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $103.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $71.28 | 2021-2023 | Benlysta |
| Genzyme Corporation | $61.04 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.21 | 2021-2025 | |
| Baxter Healthcare | $54.81 | 2022-2023 | Renal - Pd |
| Alnylam Pharmaceuticals INC. | $51.76 | 2020-2024 | Amvuttra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $35.85 | 2021-2025 | Filspari |
| Ardelyx, INC. | $32.71 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.70 | 2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $22.27 | 2025 | Tryvio |
| Shire North American Group INC | $21.21 | 2019 | |
| Daiichi Sankyo INC. | $18.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angus Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.